OPKO Health, Inc. (NASDAQ:OPK) CEO Purchases $115,312.14 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 67,434 shares of the stock in a transaction on Friday, February 28th. The shares were acquired at an average price of $1.71 per share, for a total transaction of $115,312.14. Following the acquisition, the chief executive officer now owns 213,301,448 shares of the company’s stock, valued at approximately $364,745,476.08. The trade was a 0.03 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The shares were acquired at an average price of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.48 per share, with a total value of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.59 per share, with a total value of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.56 per share, with a total value of $780,000.00.

OPKO Health Price Performance

OPK opened at $1.74 on Friday. The firm has a market cap of $1.19 billion, a P/E ratio of -9.16 and a beta of 1.63. The firm has a 50-day moving average of $1.55 and a 200 day moving average of $1.55. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $1.84.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. On average, research analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on OPK. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Wednesday, January 8th.

Institutional Investors Weigh In On OPKO Health

Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC raised its stake in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new stake in OPKO Health in the third quarter valued at approximately $45,000. Cibc World Markets Corp purchased a new stake in OPKO Health in the fourth quarter valued at approximately $45,000. Zacks Investment Management purchased a new stake in OPKO Health in the fourth quarter valued at approximately $49,000. Finally, Private Advisor Group LLC raised its stake in OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 25,000 shares in the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.